UTIBRON NEOHALER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for UTIBRON NEOHALER (UTIBRON NEOHALER).
Long-acting muscarinic antagonist (LAMA); inhibits acetylcholine at M3 receptors in bronchial smooth muscle, causing bronchodilation.
| Metabolism | Primarily hepatic via cytochrome P450 enzymes (CYP2D6 and CYP3A4); also metabolized via ester hydrolysis and direct glucuronidation. |
| Excretion | Primarily fecal (58% of radiolabeled dose) and renal (22%) after intravenous administration, with unchanged drug as minor component. Biliary excretion accounts for fecal elimination. |
| Half-life | Terminal elimination half-life: 22 hours (range 16–33 h) in patients with COPD; supports once-daily dosing. |
| Protein binding | 94–95% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Vdss: 179 L (approximately 2.6 L/kg assuming 70 kg); indicates extensive tissue distribution. |
| Bioavailability | Inhalation: absolute bioavailability ~25% (lung delivery); oral bioavailability <1% (due to first-pass metabolism and low absorption). |
| Onset of Action | Inhalation: 5 minutes (FEV1 improvement); peak effect at 1–2 hours. |
| Duration of Action | 24 hours (bronchodilation maintained over 24 h with once-daily dosing). |
| Molecular Weight | 475.4 |
1 inhalation (27.5 mcg glycopyrrolate/12.5 mcg formoterol fumarate) twice daily via oral inhalation.
| Dosage form | POWDER |
| Renal impairment | No dosage adjustment recommended for GFR 30 mL/min or greater; avoid use in severe renal impairment (GFR <30 mL/min) due to lack of data. |
| Liver impairment | No dosage adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B); not studied in severe impairment (Child-Pugh C), use with caution. |
| Pediatric use | Not approved for pediatric patients; safety and efficacy not established in children. |
| Geriatric use | No specific dosage adjustment required; monitor for anticholinergic and beta2-adrenergic adverse effects in elderly due to possible increased sensitivity. |
| 1st trimester | There are no adequate and well-controlled studies in pregnant women. Animal studies have shown no evidence of harm at clinically relevant exposures. Umeclidinium is not recommended during the first trimester unless clearly needed. |
| 2nd trimester | There are no adequate and well-controlled studies in pregnant women. Animal studies have shown no evidence of harm at clinically relevant exposures. Use only if potential benefit justifies potential risk to fetus. |
| 3rd trimester | There are no adequate and well-controlled studies in pregnant women. Animal studies have shown no evidence of harm at clinically relevant exposures. Use only if potential benefit justifies potential risk to fetus. Close monitoring is recommended during labor and delivery. |
Clinical note
Comprehensive clinical and safety monograph for UTIBRON NEOHALER (UTIBRON NEOHALER).
| Placental transfer | The molecular weight (about 475 Da) suggests potential for placental transfer. In animal studies, umeclidinium was shown to cross the placenta. No specific human data are available. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to umeclidinium or any component of the product
| Precautions | Paradoxical bronchospasm, Worsening of narrow-angle glaucoma, Urinary retention, Immediate hypersensitivity reactions |
| Food/Dietary | No significant food-drug interactions identified. Avoid grapefruit juice only if there is potential for CYP3A4 interaction; indacaterol is partially metabolized by CYP3A4, but clinically relevant interactions with grapefruit are not established for this product. Take with or without food. |
| Clinical Pearls |
Loading safety data…
| Breastfeeding |
| It is not known whether umeclidinium is excreted in human milk. Due to the low molecular weight, excretion into breast milk is possible. Caution should be exercised when administered to a nursing woman. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for UTIBRON NEOHALER and any potential adverse effects on the breastfed child. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, glycopyrrolate and indacaterol (components of Utibron Neohaler) showed no teratogenic effects at exposures up to 50 times the maximum recommended human inhalation dose (MRHDID). However, beta-2 agonists may cause fetal harm (e.g., premature labor, low birth weight). Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. |
| Fetal Monitoring | Monitor maternal respiratory status, heart rate, blood pressure, and serum potassium (beta-agonist may cause hypokalemia). Fetal monitoring for heart rate and growth if used long-term or in preterm labor risk. |
| Fertility Effects | No human studies. In animal studies, no impairment of fertility was observed with glycopyrrolate or indacaterol at doses up to 50 times MRHDID. |
| UTIBRON NEOHALER (glycopyrrolate/indacaterol) is a fixed-dose LAMA/LABA combination for maintenance treatment of COPD. Do not use for acute exacerbations. Capsules must be administered only via the Neohaler device; do not swallow. Monitor for paradoxical bronchospasm, hypersensitivity reactions, and cardiovascular effects (e.g., increased blood pressure, heart rate). Use with caution in patients with narrow-angle glaucoma, urinary retention, or severe hepatic impairment. |
| Patient Advice | This medication is for maintenance treatment of COPD, not for sudden breathing problems. Always have a rescue inhaler (e.g., albuterol) for acute symptoms. · Do not swallow the capsules; they must be placed in the Neohaler device and punctured before inhalation. · Rinse your mouth with water after each dose to help prevent thrush (oral fungal infection). · Avoid spraying the medication into your eyes; if contact occurs, rinse eyes with water and seek medical advice. · Tell your healthcare provider if you have glaucoma, prostate problems, or trouble urinating before using this medication. · Do not use more than one capsule twice daily; extra doses increase the risk of side effects. · Follow your healthcare provider's instructions for regular COPD management and monitor your symptoms. |